Magnesium glycerophosphate

Amber-G

Brand Name(s):Neomag
MagnaPhos Range
Mag-4
LiquaMag GP

Indication:Hypomagnesaemia

Rationale:

Considered:Jun-17

Review Date:Jul-22

Comments:
Primary Care must receive a comprehensive treatment plan before prescribing is transfered to the GP
Treatment should be initiated under the supervision of a physician experienced in the management of hypomagnesaemia.

For those patients who receive their prescription from Primary Care, a detailed clinical management plan must be provided by the Specialist which includes details on:
(a) Review and followup process by Specialist
(b) Therapeutic monitoring process – the undertaking of this & interpretation of results should remain the responsibility of the Specialist